Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.
TipRanks on MSN12h
iX Biopharma’s iXB 401: A Breakthrough in Drug DeliveryX Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...
NBC Los Angeles on MSN20h
FDA weighs in on diet drug shortage, creating more confusion about compoundingAs millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.
Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...
7hon MSNOpinion
The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...
Aloe vera is a natural supplement that has been shown to lower blood glucose levels and improve cholesterol profiles. Aloe ...
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...
The FDA has approved a new drug called revumenib that can be taken orally to treat acute leukemia in patients 1 year or older. The drug will be marketed under the brand name Revuforj.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback